SourceOne Global Partners has announced the strategic launch of the VESIsorb® naturally self-assembling association colloidal delivery system for ubiquinol-QH in the medical professional channel of distribution. Douglas Laboratories, Pittsburgh, PA, a member of the Atrium Innovations Group, a premier worldwide firm known for its leadership in innovating technology, has partnered with SourceOne and is first to market.
“Finding novel ways to significantly improve the absorption of fat-soluble compounds has always been a challenge,” observed Dr. Andrew Halpner, Vice President of New Product Development and Technical Services for Douglas Laboratories. “The VESIsorb® naturally self-assembling association colloidal delivery system addresses the low relative bioavailability of natural bio-actives like ubiquinol-QH, which inherently exhibits poor water solubility but high membrane permeability.”
Ubiquinol-QH is the biologically reduced form of coenzyme Q10 ubiquinone. Ubiquinone can be converted in the body to ubiquinol-QH.
“While ubiquinone plays a valuable role in health and can be utilized by the body, recent studies indicate that as people age, the body’s ability to convert ubiquinone to ubiquinol-QH begins to decline,” Dr. Halpner commented. “Since this nutrient plays critical roles in antioxidant, energy and cardiovascular function, ubiquinol-QH is of special importance to older adults looking to support normal aging and cardiovascular function.”
Dr. Robert Barry, Director of Scientific Affairs for Kaneka Nutrients L.P., in his book, “The Power of KanekaQH™ (Ubiquinol)” explains, “Cardiovascular patients, those fighting age-related diseases and even healthy people over the age of 40 have a critical need to optimize their plasma CoQ10 levels.”
Douglas Laboratories has introduced KanekaQH™ ubiquinol in a formula with the VESIsorb® delivery system. It is delivered in a novel, proprietary, two-piece liquid-filled hard-shell capsule called Caplique™, an exclusive from AquaCap, a member of Atrium Innovations’ family of companies.
Douglas Lioon, CEO of Douglas Laboratories, explained, “We look for technologies and ingredients that have outstanding scientific evidence. After all, a physician’s entire reputation is on the line when recommending professional dietary supplements for cardiovascular support like ubiquinol-QH with the VESIsorb® technology. As more patients look to support their cardiovascular health and their physicians seek to integrate nutraceuticals, our ubiquinol-QH will be an effective tool in the patient-care matrix.”
Developed by Vesifact of Baar, Switzerland, VESIsorb® is protected worldwide by multiple U.S. and international granted and pending patents.
The peer-reviewed journal, Alternative Therapies in Health and Medicine, recently published the results of a double-blind study comparing the bioavailability of patented CoQsource® Bio-Enhanced CoQ10 (exclusive brand of SourceOne) to that of other “bio-enhanced” CoQ10 formulations. The study, entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System,” appears in the March/April, 2009 issue, Vol. 15, No. 2.
In this study, the relative bioavailability of a single oral dose of 120mg of CoQ10 was assessed using the area under curve (AUC (0-10h)) where the value for CoQsource® reached 30.62 µg/ml/10h; a far superior 622% higher bioavailability than the oil-based formula.
A pharmacokinetic pilot study (single oral dose, crossover) in humans comparing ubiquinol-QH to the same ubiquinol-QH in the VESIsorb® delivery system (CoQsource® QH exclusively from SourceOne) demonstrated an increase of 696% in peak blood levels (cmax) of ubiquinol. The relative bioavailability calculated using the area under the curve (AUC0-24h) was also increased by 485%.
“The ability to offer bio-enhanced water-soluble ingredients such as CoQ10 in either ubiquinol-QH or ubiquinone form, Omega-3 concentrated EPA/DHA, citrus polymethoxylated flavones (PMFs), resveratrol, vitamin D, palm tocotrienols, and more to the dietary supplement, functional food and beverage markets has set a new benchmark for the industry,” said Halpner.
In addition to offering a Caplique™, SourceOne also makes CoQsource® (ubiquinol-QH and ubiquinone) available in soft gels and as a powder for capsules, drink mixes, stick packs and more.
Jesse Lopez, founder and CEO of SourceOne commented, “We remain committed to advancing innovative technologies and proprietary formulations of natural products that maximize the many health benefits they offer to the medical community and the growing numbers of health conscious consumers worldwide. Our mission is clear, and we continue to vigorously pursue our goal of turning good ingredients into great ingredients.”
About SourceOne™ Global Partners
SourceOne Global Partners, headquartered in Chicago, IL, is a leading supplier of innovative, science-based, branded ingredients and proprietary formulas to the nutritional supplement, functional food & beverage, cosmetic, and animal nutrition markets. SourceOne has assembled an impressive and enviable portfolio of complementary condition-specific ingredients that address the most pressing health concerns, including heart health, glucose management, cognitive function, diet and energy, and general wellness.
SourceOne is recognized as a leader in delivering the best science nature has to offer through health solutions such as the award-winning Cholesstrinol™ Family of Heart Healthy Formulas, OmegaChoice™ Concentrated Marine Omega-3 EPA/DHA (EFAs), CoQsource® Bio-Enhanced Coenzyme Q10, and SterolSource® Phytosterols. The SourceOne product line continues to expand and also includes TocoSource® Palm Tocotrienols, GammaSource® Mixed Tocopherols, PMF-source™ Citrus Flavonoids (PMF), Tongkat Ali-Source™ LJ100 as well as green tea, resveratrol, chondroitin, natural carotenoids, and more.
About Douglas Laboratories
With worldwide headquarters located in Pittsburgh, PA, Douglas Laboratories currently offers approximately 700 branded nutraceutical products along with new products introduced on a continuing basis. Working with an experienced research staff of PhDs and a world-renowned medical advisory board, Douglas Laboratories’ commitment to bring innovative, clinically supported products to the marketplace to support patient needs is unsurpassed.
About Vesifact AG
A vital link between current research and private industry, Vesifact is a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zürich). Innovative technology and know-how are developed in Vesifact’s laboratories and upscaled at its production units. They are then applied to commercial products before being transferred to the marketplace. In this way, Vesifact brings the latest know-how to exactly where it is most needed.
Vesifact laboratories and R&D facilities meet the ever increasing requirements for top-level research, product development, and innovation. Vesifact produces carrier systems that take medical, nutraceuticals, and cosmetic ingredients to enhance performance. Vesifact thus fulfils ever-increasing requirements for innovative dosage forms and application technologies and offers cutting edge-solutions.